Renal Function. No consistent changes in median urine albumin
to creatinine ratio occurred in either treatment group during
the 4-year period. Most patients had normoalbuminuria at
baseline. A similar proportion of patients in the dapagliflozin
group experienced apparent improvement of glomerular function
(shift from microalbuminuria to normoalbuminuria or
shift from macroalbuminuria to microalbuminuria or normoalbuminuria)
from baseline to week 208 (last observation
carried forward) to that proportion who experienced apparent
deterioration of glomerular function (shifts in the opposite
direction). In the glipizide group, slightly more patients experienced
glomerular function deterioration than improvement.
Overall, renal variables showed no signs of decreasing renal
function associated with dapagliflozin treatment.